Ms. Campbell brings over 25 years of pharmaceutical commercialization experience and joins Merus from Novartis Pharmaceuticals Corporation, where she led Novartis's U.S. Oncology Solid Tumor Franchise and was responsible for a broad portfolio of therapies in oncology and rare diseases. Prior to Novartis, Ms. Campbell was with Bayer HealthCare Pharmaceuticals, where she was instrumental in helping to build, launch and lead Bayer's U.S. Oncology business. Cash Runway, Merus expects to be funded beyond 2024 Based on the Company's current operating plan, Merus expects our existing cash, cash equivalents and marketable securities will fund Merus' operations beyond 2024. Annual General Meeting and Board of Directors The Company's annual general meeting of shareholders (AGM) is planned to be held on May 31, 2022.